Inactive Instrument

AXIM Biotechnologies, Inc. Stock price Other OTC

Equities

AXIM

US05463V1008

Biotechnology & Medical Research

Sales 2021 60.46K Sales 2022 8.88K Capitalization 5.16M
Net income 2021 -16M Net income 2022 -6M EV / Sales 2021 1,092 x
Net Debt 2021 6.3M Net Debt 2022 5.64M EV / Sales 2022 1,218 x
P/E ratio 2021
-3.55 x
P/E ratio 2022
-0.69 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 66.74%
More Fundamentals * Assessed data
Dynamic Chart
AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding CI
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.75 million in funding from Medical Marijuana, Inc. CI
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test CI
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide CI
AXIM Biotechnologies, Inc. announced that it has received $20 million in funding CI
AXIM Biotechnologies, Inc. Appoints Kurt Phinney as Chief Operating Officer CI
AXIM Biotechnologies, Inc. announced that it has received $0.575 million in funding CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
AXIM Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt CI
More news
Managers TitleAgeSince
Chief Executive Officer 68 -
Director of Finance/CFO 55 16-06-28
Chief Operating Officer - 23-05-22
Members of the board TitleAgeSince
Chief Executive Officer 68 -
Director/Board Member 71 17-05-17
Director/Board Member 76 17-05-17
More insiders
Axim Biotechnologies, Inc. is an international healthcare diagnostic solutions development company. The Company is focused on improving the landscape for the diagnosis of ophthalmological conditions such as dry eye disease (DED) through rapid diagnostic tests. It has developed and commercialized two highly specialized point-of-care (POC) diagnostic tests, Ocular Immunoglobulin E (IgE) test and Lactoferrin test, which are designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient DED and non-specific allergic conjunctivitis. In addition, it is also engaged in the development of a quantitative tear MMP-9 test to measure the intensity of inflammation affecting dry eye patients. It has also developed proprietary assays for the detection of QSOX1-L in patients undergoing cancer treatment. Its products also include SARS-CoV-2 neutralizing antibody tests and a fentanyl neutralizing antibody test.
More about the company
  1. Stock
  2. Equities
  3. Stock AXIM Biotechnologies, Inc.
  4. Stock AXIM Biotechnologies, Inc. - Other OTC